Ptosis News and Research

RSS

Novel breast cancer surgical technique now available in New England

Jennifer Gass, MD, chief of surgery at Women & Infants Hospital of Rhode Island and a breast surgeon with the Breast Health Center in the hospital's Program in Women's Oncology, recently completed a one-month sabbatical in Paris with the world-renowned breast surgeon Krishna B. Clough, MD, medical director of the Paris Breast Center.

30 Nov 2011

FDA approves Merz Aesthetics' XEOMIN for temporary improvement of glabellar lines

Merz Aesthetics today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved XEOMIN for the temporary improvement in the appearance of moderate to severe glabellar lines, or frown lines between the eyebrows, in adult patients.

22 Jul 2011

Botox injections can reduce wrinkles with half as many sessions after 20 months

Patients receiving Botox Cosmetic treatments can reduce wrinkles with half as many sessions after 20 months, according to research conducted at Oregon Health & Science University's Casey Eye Institute.

15 Jun 2011

Merz to present data on Xeomin clinical studies for cervical dystonia at AAPM&R

Merz Pharmaceuticals announced today that data from stability and clinical studies evaluating Xeomin (incobotulinumtoxinA), a botulinum toxin type A free from accessory proteins, will be presented at the 71st Annual Assembly of the American Academy of Physical Medicine and Rehabilitation (AAPM&R) in Seattle, Wash.

8 Nov 2010

FDA approves BOTOX as prophylactic treatment for Chronic Migraine

Allergan, Inc. today announced the United States Food and Drug Administration (FDA) has approved BOTOX(onabotulinumtoxinA) for the prophylactic (preventive) treatment of headaches in adults with Chronic Migraine.

18 Oct 2010

Xeomin botulinum toxin for cervical dystonia now available in the U.S.

Merz Pharmaceuticals today announced that Xeomin (incobotulinumtoxinA), a new botulinum toxin type A for the treatment of adults with cervical dystonia (CD)or blepharospasm, is now commercially available in the U.S. XEOMIN was approved by the U.S. Food and Drug Administration (FDA) on July 30, 2010.

6 Oct 2010

Xeomin receives FDA approval for treatment of cervical dystonia

Merz Pharmaceuticals today announced that the United States Food and Drug Administration has approved Xeomin (incobotulinumtoxinA), a botulinum toxin type A for the treatment of adults with cervical dystonia or blepharospasm. According to an epidemiology study conducted in Rochester, Minnesota, the prevalence of focal dystonia, which includes cervical dystonia and blepharospasm, is estimated at 295 per million people in the U.S.

2 Aug 2010

Simple test detects early evidence of amblyopia in infants too young for conventional vision testing

In children with vascular birthmarks around the eye, even partial blockage of vision can lead to visual loss due to amblyopia.

1 Apr 2009

New botulinum toxin type A (Reloxin) appears to be well tolerated and may help reduce forehead wrinkles

Injections with a new type of botulinum toxin appears to be well tolerated and may help to improve the appearance of moderate to severe forehead lines with no evidence of diminishing treatment response over 13 months, according to a report in the March/April issue of Archives of Facial Plastic Surgery.

16 Mar 2009